GS030-DP

DB17847InvestigationalGene Therapies

GS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa. It targets retinal ganglion cells that encodes a light-sensitive channelrhodopsin, ChrimsonR-tdTomato (ChR-tdT), delivered by an AAV2.7m8... It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.

Code names: GS030-DP

What you can answer from here — as of April 23, 2025

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of GS030-DP, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account